Core Insights - The company reported a revenue of approximately 353 million yuan for the first half of 2025, representing a year-on-year growth of 17.3% [1] - Gross profit reached 248 million yuan, with a year-on-year increase of 13.14% [1] - Research and development expenses amounted to about 116 million yuan, reflecting a year-on-year growth of 15.1% [1] Revenue Growth Drivers - The sustainable revenue growth is primarily attributed to strong sales growth in the transcatheter valve therapy and neurointervention businesses [1] - Sales revenue from TAVR-related products increased by 24.0% to 162 million yuan, driven by market share gains in the Chinese TAVR market and a shift towards newly launched high-end products [1] - Total terminal implants exceeded 2,050 units, marking a year-on-year growth of approximately 18.8%, surpassing market growth [1] Neurointervention Product Performance - Sales revenue from neurointervention products rose by 12.2% to 192 million yuan, with key drivers including deeper market penetration of existing products and the successful launch of the newly approved YonFlow® blood flow-directed stent [1] - The DCwire® microcatheter significantly expanded market share with a revenue growth of nearly 140% during the reporting period [2] - The YonFlow® blood flow-directed stent received regulatory approval in April 2025 and has been actively marketed, achieving its first commercial implant by June 2025 [2]
沛嘉医疗-B(09996)公布中期业绩 实现收入约3.53亿元 同比增长17.3%